Metastatic Castration Sensitive Prostate Cancer Mcspc clinical trials

Explore recruiting metastatic castration sensitive prostate cancer mcspc clinical trials.

Recruiting metastatic castration sensitive prostate cancer mcspc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castration Sensitive Prostate Cancer Mcspc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01).

Belgium, Netherlands, Germany, Sweden, Finland, Poland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Germany, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Bulgaria, Czechia, Poland, Hungary, Sweden, Italy +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Castration Sensitive Prostate Cancer Mcspc trials by city

Metastatic Castration Sensitive Prostate Cancer Mcspc clinical trials

Recruiting metastatic castration sensitive prostate cancer mcspc studies right now

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Also recruiting in Europe

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01).

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Metastatic Castration Sensitive Prostate Cancer Mcspc trials by city

Other conditions